Study title
Matchpoint - Ponatinib and Intensive Chemotherapy
Scientific title
Management of Transformed Chronic myeloid leukaemia: Ponatinib and intensive chemotherapy: a dose finding study (Clinicaltrialsregister.eu 2012-005629-65)
Indication and most important inclusion criteria
Male or female patients of 16 years of age or older with Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) in blast phase (BP).
Patients can be considered for inclusion in the study if they are suitable for intensive chemotherapy, have adequate kidney and liver function as well as normal pancreas function.
Short description of intervention
The aim of this trial is to find a safe and effective dose of a drug called ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase.
Type of study
Treatment of advanced phases
Current status
No longer recruiting
Study sponsor
University of Birmingham
Scientific lead / contact
Professor Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD
Principal investigator
Prof. Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD
Additional information
Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)
Study description on the website of Cancer Research UK
Study centers / principal investigators
United Kingdom
University of Birmingham
CRCTU, Institute of Cancer and Genomic Sciences
Edgbaston, B15 2TH
Glasgow
Leeds
Liverpool
London
Nottingham
Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
Inclusion criteria
Inlusion criteria define which subjects may participate in a clinical study. Study subjects must fulfill all inclusion criteria (e.g. with regard to sex, age, previous diseases). This ensures a uniform composition of the study population and minimizes the risk of influences that distort the study results.
Chemotherapy
Chemotherapy is the use of drugs to treat cancer by destroying or slowing the growth of fast-growing cancer cells. The term chemotherapy also includes treatment with antibiotics.
Indication
In medicine, a reason to use a certain diagnostic test, therapeutic procedure or medication. The opposite of indication is contraindication.
Ponatinib
Trade name: Iclusig, development name: AP24534; a third-generation tyrosine kinase inhibitor
Other names: AP24534|Iclusig.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Blast
An immature white blood cell that normally represents an early phase of the development process of a blood stem cell in the bone marrow
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
